Randomized [resa]    
Phase II Study [resa]    
Placebo [topp]    
Plus [ftcn]    
Best [qlco]    
Supportive Care [topp]    
SECOND LINE TREATMENT [topp]    
Advanced [qlco]    
HEPATOCELLULAR CARCINOMA [neop]    
Plus [ftcn]    
Best [qlco]    
Supportive Care [topp]    
Failed [ftcn]    
Meet [phpr]    
Primary Endpoint [irda]    
Survival [acty]    
SECOND LINE TREATMENT [topp]    
Advanced [qlco]    
HEPATOCELLULAR CARCINOMA [neop]    
Randomized [resa]    
Phase II Study [resa]    
ARM [blor]    
Improved [qlco]    
Progression-Free Survival [qnco]    
Time to Progression [tmco]    
Tumour NOS [neop]    
Benefit [qnco]    
Compared [acty]    
Placebo [topp]    
ARM [blor]    
Acceptable [qlco]    
Safety [hcpp]    
Profile [lbpr]    
Efficacy [qlco]    
Safety [hcpp]    
selection [genf]    
Inhibitor [qlco]    
Combined [qlco]    
Best [qlco]    
Supportive Care [topp]    
Evaluated [hlca]    
Global [spco]    
Randomized [resa]    
placebo-controlled [resa]    
PHASE II TRIAL [resa]    
Patients [podg]    
Locally [spco]    
Advanced [qlco]    
Metastatic hepatocellular carcinoma [neop]    
Patients [podg]    
Methods [inpr]    
Patients [podg]    
HEPATOCELLULAR CARCINOMA [neop]    
Child-Pugh [inpr]    
Class [inpr]    
progressed [ftcn]    
Intolerant [ftcn]    
Prior Therapy [clna]    
Stratified [qlco]    
Tumour invasion [fndg]    
Present/Absent [cnce]    
Extrahepatic [spco]    
Spread [qlco]    
Vascular [bpoc]    
Invasion [fndg]    
Region [geoa]    
ASIAN [popg]    
Randomized [resa]    
Best [qlco]    
Supportive Care [topp]    
Start [tmco]    
DOSE [qnco]    
MG [geoa]    
Twice Daily [tmco]    
Placebo [topp]    
Best [qlco]    
Supportive Care [topp]    
Primary Endpoint [irda]    
Survival [acty]    
Estimated [qnco]    
Hazard Ratio [qnco]    
Survival [acty]    
One-sided [spco]    
Stratified [qlco]    
Best [qlco]    
Supportive Care [topp]    
Placebo [topp]    
Best [qlco]    
Supportive Care [topp]    
Median [spco]    
10-14 [fndg]    
5 - 9 [fndg]    
Subgroup Analysis [resa]    
ASIAN [popg]    
{Non-patient} [clna]    
ASIAN [popg]    
absence [ftcn]    
Tumour invasion [fndg]    
Consistent [idcn]    
Improvement [cnce]    
Best [qlco]    
Supportive Care [topp]    
Observed [ftcn]    
secondary [neop]    
Efficacy [qlco]    
End Point [qlco]    
Progression-Free Survival [qnco]    
Time to Progression [tmco]    
Tumour NOS [neop]    
Benefit [qnco]    
Retained [ftcn]    
ASIAN [popg]    
Patients [podg]    
Subgroup Analysis [resa]    
Overall Response [fndg]    
Treatments [topp]    
Patient Reported Outcome [inpr]    
Placebo [topp]    
Best [qlco]    
Supportive Care [topp]    
causality [ftcn]    
adverse events [patf]    
Best [qlco]    
Supportive Care [topp]    
DIARRHOEA [sosy]    
HYPERTENSION [dsyn]    
Decreased appetite [sosy]    
baseline [bodm]    
SERUM [bdsu]    
Identified [qlco]    
NEW [qlco]    
Prognostic [inpr]    
MET [dsyn]    
predictive [qlco]    
stromas [bpoc]    
Derived [qlco]    
Survival [acty]    
Conclusions [idcn]    
Best [qlco]    
Supportive Care [topp]    
Survival [acty]    
Placebo [topp]    
Best [qlco]    
Supportive Care [topp]    
Stratification [resa]    
subgroups [virs]    
Best [qlco]    
Supportive Care [topp]    
Long [qlco]    
Progression-Free Survival [qnco]    
Time to Progression [tmco]    
Tumour NOS [neop]    
Higher [qlco]    
Benefit [qnco]    
Acceptable [qlco]    
toxicity [qlco]    
Patients [podg]    
Advanced [qlco]    
HEPATOCELLULAR CARCINOMA [neop]    
Trial [resa]    
Registration [hlca]    
GOV [gngm]    
